1 |
HDAC6
| [4] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Amyotrophic lateral sclerosis, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
2 |
HDAC5
| [5] Apelin signaling pathway Apelin signaling pathway, Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis, MicroRNAs in cancer | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
3 |
SIGMAR1
| [2] Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
4 |
CD52
| - | D02802
D02802
|
Alemtuzumab
| [7] 96 96, 164, 234, 283, 284, 285, 326 |
5 |
CNR1
| [4] Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D00306
D00306
|
Dronabinol
| [8] 2 2, 8, 13, 36, 46, 96, 271, 298 |
6 |
CNR1
| [4] Rap1 signaling pathway Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling | D10915
D10915
|
Cannabidiol
| [20] 2 2, 6, 8, 13, 36, 46, 51, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
7 |
CNR2
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00306
D00306
|
Dronabinol
| [3] 96 96, 271, 298 |
8 |
CNR2
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D10915
D10915
|
Cannabidiol
| [12] 96 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
9 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
10 |
ADORA1
| [7] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
11 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
12 |
ADORA2A
| [7] Rap1 signaling pathway Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
13 |
CSF2RA
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D05803
D05803
|
Sargramostim
| [7] 6 6, 28, 60, 62, 96, 229, 285 |
14 |
CSF3R
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D03235
D03235
|
Filgrastim
| [35] 2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
15 |
ADRA1D
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
16 |
ADRA1B
| [6] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
17 |
ADRA1A
| [7] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
18 |
CTLA4
| [4] Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, Autoimmune thyroid disease, Rheumatoid arthritis | D06657
D06657
|
Tremelimumab
| [1] 96 96 |
19 |
ADRA2A
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
20 |
ADRA2B
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
21 |
ADRA2C
| [2] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
22 |
ADRB1
| [11] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
23 |
ADRB2
| [9] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
24 |
ADRB3
| [8] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D00095
D00095
|
Epinephrine
| [3] 46 46, 70, 96 |
25 |
ACE
| [6] Renin-angiotensin system Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy | D00251
D00251
|
Captopril
| [8] 6 6, 17, 46, 86, 96, 97, 107, 271 |
26 |
DHFR
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
27 |
AGTR1
| [16] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D08146
D08146
|
Losartan
| [17] 17 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
28 |
S1PR1
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
29 |
S1PR1
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
30 |
S1PR3
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
31 |
S1PR3
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
32 |
ELANE
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Systemic lupus erythematosus | D03788
D03788
|
Sivelestat
| [3] 13 13, 85, 96 |
33 |
DHFR2
| [5] One carbon pool by folate One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance | D00142
D00142
|
Methotrexate
| [38] 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
34 |
ESR1
| [9] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
35 |
ESR2
| [7] Endocrine resistance Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
36 |
FDPS
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D01968
D01968
|
Zoledronic acid
| [13] 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
37 |
FDPS
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D08484
D08484
|
Risedronic acid
| [9] 46 46, 50, 66, 93, 95, 96, 107, 113, 274 |
38 |
FDPS
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection | D08689
D08689
|
Zoledronic acid
| [13] 5 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333 |
39 |
MTOR
| [51] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| [40] 2 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331 |
40 |
MTOR
| [51] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D02714
D02714
|
Everolimus
| [9] 34 34, 67, 89, 96, 137, 157, 158, 228, 277 |
41 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
42 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
43 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
44 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
45 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
46 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
47 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
48 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
49 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
50 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
51 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
52 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
53 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
54 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
55 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
56 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D03297
D03297
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
57 |
GRIN1
| [18] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
58 |
GRIN2A
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
59 |
GRIN2B
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
60 |
GRIN2C
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
61 |
GRIN2D
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D03742
D03742
|
Dextromethorphan
| [11] 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
62 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00244
D00244
|
Betamethasone
| [2] 96 96, 235 |
63 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00246
D00246
|
Budesonide
| [5] 96 96, 97, 98, 228, 299 |
64 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| [9] 96 96, 97, 162, 222, 235, 257, 283, 296, 299 |
65 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00385
D00385
|
Triamcinolone
| [5] 96 96, 107, 162, 226, 298 |
66 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00407
D00407
|
Methylprednisolone
| [14] 96 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
67 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| [12] 96 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
68 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00473
D00473
|
Prednisone
| [16] 96 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
69 |
HDAC1
| [15] Cell cycle Cell cycle, Longevity regulating pathway - multiple species, Notch signaling pathway, Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Huntington disease, Amphetamine addiction, Alcoholism, Human papillomavirus infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chronic myeloid leukemia | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
70 |
HDAC2
| [15] Cell cycle Cell cycle, Longevity regulating pathway - multiple species, Notch signaling pathway, Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Huntington disease, Amphetamine addiction, Alcoholism, Human papillomavirus infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chronic myeloid leukemia | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
71 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D07474
D07474
|
Atorvastatin
| [19] 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 |
72 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D08410
D08410
|
Pravastatin
| [9] 13 13, 46, 49, 67, 79, 96, 164, 265, 333 |
73 |
HMGCR
| [4] Terpenoid backbone biosynthesis Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion | D08492
D08492
|
Rosuvastatin
| [11] 6 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299 |
74 |
HPRT1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00161
D00161
|
Mercaptopurine
| [4] 65 65, 96, 97, 164 |
75 |
HPRT1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D04931
D04931
|
Mercaptopurine
| [4] 65 65, 96, 97, 164 |
76 |
HRH1
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00494
D00494
|
Promethazine
| [1] 96 96 |
77 |
HTR4
| [4] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse | D08236
D08236
|
Mosapride
| [1] 96 96 |
78 |
HTR4
| [4] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse | D09205
D09205
|
Prucalopride
| [3] 13 13, 51, 96 |
79 |
IFNAR1
| [18] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D03305
D03305
|
Interferon alfa
| [6] 13 13, 25, 26, 28, 56, 96 |
80 |
IFNAR1
| [18] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| [4] 13 13, 26, 96, 97 |
81 |
IFNAR2
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D03305
D03305
|
Interferon alfa
| [6] 13 13, 25, 26, 28, 56, 96 |
82 |
IFNAR2
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| [4] 13 13, 26, 96, 97 |
83 |
IGF1R
| [29] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Oocyte meiosis, Autophagy - animal, Endocytosis, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Focal adhesion, Adherens junction, Signaling pathways regulating pluripotency of stem cells, Long-term depression, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Glioma, Prostate cancer, Melanoma, Breast cancer, Hepatocellular carcinoma | D03297
D03297
|
Mecasermin
| [6] 65 65, 78, 96, 168, 265, 299 |
84 |
IL2RA
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
85 |
IL2RB
| [11] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
86 |
IL2RG
| [12] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | D00748
D00748
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 |
87 |
IL6
| [51] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | D12487
D12487
|
Olokizumab
| [2] 46 46, 96 |
88 |
IL11RA
| [3] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage | D05266
D05266
|
Oprelvekin
| [2] 96 96, 288 |
89 |
IL12A
| [25] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
90 |
IL12B
| [25] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
91 |
IMPDH1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00752
D00752
|
Mycophenolate mofetil
| [34] 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
92 |
IMPDH1
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D05096
D05096
|
Mycophenolic acid
| [36] 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
93 |
IMPDH2
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D00752
D00752
|
Mycophenolate mofetil
| [34] 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
94 |
IMPDH2
| [4] Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D05096
D05096
|
Mycophenolic acid
| [36] 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
95 |
INSR
| [22] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Adherens junction, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy | D03230
D03230
|
Insulin human
| [2] 96 96, 156 |
96 |
ITGA4
| [14] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D06886
D06886
|
Natalizumab
| [6] 13 13, 15, 25, 46, 63, 96 |
97 |
ITGA4
| [14] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
98 |
ITGA4
| [14] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
99 |
AR
| [4] Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D08409
D08409
|
Prasterone
| [6] 49 49, 53, 83, 86, 96, 113 |
100 |
ITGAL
| [12] Rap1 signaling pathway Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis | D03959
D03959
|
Efalizumab
| [9] 11 11, 13, 37, 46, 49, 53, 61, 95, 96 |
101 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D08083
D08083
|
Vedolizumab
| [3] 94 94, 96, 97 |
102 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D09901
D09901
|
Etrolizumab
| [2] 96 96, 97 |
103 |
ITGB7
| [11] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D10540
D10540
|
Abrilumab
| [2] 96 96, 97 |
104 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
105 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10871
D10871
|
Filgotinib
| [6] 46 46, 53, 96, 97, 222, 271 |
106 |
JAK1
| [27] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10994
D10994
|
Upadacitinib
| [8] 40 40, 41, 46, 49, 96, 97, 107, 271 |
107 |
JAK2
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
108 |
JAK3
| [15] Chemokine signaling pathway Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
109 |
KIT
| [11] MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer | D10229
D10229
|
Masitinib
| [6] 2 2, 5, 6, 13, 46, 96 |
110 |
SMAD7
| [2] TGF-beta signaling pathway TGF-beta signaling pathway, Hippo signaling pathway | D10956
D10956
|
Mongersen
| [2] 96 96, 97 |
111 |
ATP4A
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| [14] 6 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299 |
112 |
ATP4B
| [4] Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| [14] 6 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299 |
113 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| [13] 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
114 |
OPRK1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| [3] 96 96, 97, 226 |
115 |
OPRM1
| [3] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction | D05113
D05113
|
Naltrexone
| [13] 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
116 |
IL22
| [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | D11953
D11953
|
Efmarodocokin alfa
| [2] 96 96, 97 |
117 |
PDCD1
| [3] Cell adhesion molecules Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10316
D10316
|
Nivolumab
| [12] 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
118 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
119 |
PDE2A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
120 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
121 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
122 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
123 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
124 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00302
D00302
|
Dipyridamole
| [6] 46 46, 49, 51, 66, 96, 224 |
125 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
126 |
PDE4A
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
127 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
128 |
PDE4B
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
129 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
130 |
PDE4C
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
131 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
132 |
PDE4D
| [5] Purine metabolism Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
133 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
134 |
PDE1B
| [7] Purine metabolism Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
135 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D09214
D09214
|
Ustekinumab
| [16] 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
136 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10438
D10438
|
Guselkumab
| [5] 37 37, 41, 51, 96, 97 |
137 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D10912
D10912
|
Brazikumab
| [2] 96 96, 97 |
138 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11052
D11052
|
Risankizumab
| [4] 37 37, 96, 97, 271 |
139 |
IL23A
| [9] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | D11123
D11123
|
Mirikizumab
| [3] 37 37, 96, 97 |
140 |
HDAC7
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
141 |
S1PR5
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
142 |
S1PR5
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
143 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08378
D08378
|
Pioglitazone
| [17] 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
144 |
PPP3CA
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
145 |
PPP3CA
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
146 |
PPP3CB
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
147 |
PPP3CB
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
148 |
PPP3CC
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
149 |
PPP3CC
| [33] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
150 |
PPP3R1
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
151 |
PPP3R1
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
152 |
PPP3R2
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D00107
D00107
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
153 |
PPP3R2
| [32] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | D08556
D08556
|
Tacrolimus
| [34] 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
154 |
HDAC8
| [4] Cell cycle Cell cycle, Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
155 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| [12] 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
156 |
RARA
| [5] Th17 cell differentiation Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | D01418
D01418
|
Tamibarotene
| [2] 26 26, 96 |
157 |
RRM1
| [6] Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | D07966
D07966
|
Fludarabine
| [20] 11 11, 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
158 |
SCN1A
| [1] Dopaminergic synapse Dopaminergic synapse | D07552
D07552
|
Bupivacaine
| [4] 96 96, 168, 226, 298 |
159 |
SCN2A
| [1] Taste transduction Taste transduction | D07552
D07552
|
Bupivacaine
| [4] 96 96, 168, 226, 298 |
160 |
SCN3A
| [1] Taste transduction Taste transduction | D07552
D07552
|
Bupivacaine
| [4] 96 96, 168, 226, 298 |
161 |
SCN5A
| [1] Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes | D07552
D07552
|
Bupivacaine
| [4] 96 96, 168, 226, 298 |
162 |
SCN9A
| [1] Taste transduction Taste transduction | D07552
D07552
|
Bupivacaine
| [4] 96 96, 168, 226, 298 |
163 |
SLC6A2
| [1] Synaptic vesicle cycle Synaptic vesicle cycle | D07591
D07591
|
Bupropion
| [2] 96 96, 171 |
164 |
SLC6A3
| [7] Synaptic vesicle cycle Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism | D07591
D07591
|
Bupropion
| [5] 8 8, 18, 21, 96, 171 |
165 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D00754
D00754
|
Thalidomide
| [20] 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
166 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02597
D02597
|
Adalimumab
| [17] 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
167 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| [27] 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
168 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D03441
D03441
|
Certolizumab pegol
| [8] 37 37, 46, 49, 96, 97, 107, 226, 271 |
169 |
TNF
| [67] Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D04358
D04358
|
Golimumab
| [8] 46 46, 56, 84, 96, 97, 107, 270, 271 |
170 |
TYK2
| [16] Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 | D09970
D09970
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
171 |
TYK2
| [16] Necroptosis Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19 | D11817
D11817
|
Deucravacitinib
| [3] 49 49, 96, 97 |
172 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00129
D00129
|
Calcitriol
| [9] 18 18, 37, 46, 49, 66, 96, 158, 235, 326 |
173 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00187
D00187
|
Ergocalciferol
| [6] 46 46, 49, 84, 96, 97, 299 |
174 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| [24] 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
175 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D01518
D01518
|
Alfacalcidol
| [8] 41 41, 46, 49, 50, 96, 107, 235, 238 |
176 |
XDH
| [6] Purine metabolism Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome | D00224
D00224
|
Allopurinol
| [7] 6 6, 46, 57, 60, 66, 96, 97 |
177 |
CACNA1C
| [34] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [4] 58 58, 96, 140, 167 |
178 |
CACNA1D
| [35] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [4] 58 58, 96, 140, 167 |
179 |
CACNA1F
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [4] 58 58, 96, 140, 167 |
180 |
CACNA1S
| [27] MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | D02356
D02356
|
Verapamil
| [4] 58 58, 96, 140, 167 |
181 |
HDAC11
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
182 |
HDAC10
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
183 |
TNFSF11
| [8] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Breast cancer, Rheumatoid arthritis | D03684
D03684
|
Denosumab
| [8] 46 46, 50, 70, 93, 95, 96, 274, 299 |
184 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00302
D00302
|
Dipyridamole
| [6] 46 46, 49, 51, 66, 96, 224 |
185 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D00528
D00528
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
186 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D01453
D01453
|
Caffeine
| [8] 2 2, 6, 21, 46, 78, 96, 97, 265 |
187 |
S1PR4
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
188 |
S1PR4
| [3] FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
189 |
IL1RL2
| [1] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | D12066
D12066
|
Spesolimab
| [2] 96 96, 97 |
190 |
HDAC3
| [4] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
191 |
CD3D
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
192 |
CD3E
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
193 |
CD3G
| [10] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer | D06314
D06314
|
Visilizumab
| [2] 96 96, 97 |
194 |
S1PR2
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| [3] 96 96, 97, 98 |
195 |
S1PR2
| [2] Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10968
D10968
|
Ozanimod
| [3] 13 13, 96, 97 |
196 |
MS4A1
| [1] Hematopoietic cell lineage Hematopoietic cell lineage | D02994
D02994
|
Rituximab
| [15] 96 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
197 |
GLP2R
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D06053
D06053
|
Teduglutide
| [1] 96 96 |
198 |
CD80
| [11] Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203
D03203
|
Abatacept
| [26] 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
199 |
CD86
| [13] Virion - Adenovirus Virion - Adenovirus, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis | D03203
D03203
|
Abatacept
| [26] 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
200 |
HDAC9
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
201 |
HDAC4
| [5] Apelin signaling pathway Apelin signaling pathway, Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis, MicroRNAs in cancer | D06320
D06320
|
Vorinostat
| [2] 75 75, 96 |
202 |
NR1H4
| [1] Bile secretion Bile secretion | D00163
D00163
|
Chenodeoxycholic acid
| [3] 96 96, 234, 263 |
203 |
NR1H4
| [1] Bile secretion Bile secretion | D00734
D00734
|
Ursodeoxycholic acid
| [5] 96 96, 97, 234, 296, 299 |